Clinical Research on the efficacy evaluation and the biomarker of nivolumab to an advance malignant melanoma

Trial Profile

Clinical Research on the efficacy evaluation and the biomarker of nivolumab to an advance malignant melanoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Aug 2017

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Acronyms CREATIVE; CSPOR
  • Most Recent Events

    • 28 Aug 2015 Planned initiation date changed from 1 Jan 2015 to 1 Sep 2015 as per University Hospital Medical Information Network - Japan.
    • 27 Aug 2015 Status changed from not yet recruiting to recruiting as per University Hospital Medical Information Network - Japan.
    • 26 Feb 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top